# Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)

> **NCT05023759** · — · COMPLETED · sponsor: **Formula30A LLC** · enrollment: 30 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DIETARY_SUPPLEMENT:** Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules

## Key facts

- **NCT ID:** NCT05023759
- **Lead sponsor:** Formula30A LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-10-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023759, "Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05023759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*